Who are PRFM treatment's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intra ovarian by platelet rich plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/prfm-treatment.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PRFM treatment — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PRFM treatment (PRFM treatment) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative medicine / Autologous cell therapy. Area: Ophthalmology / Regenerative Medicine.

phase 3 Regenerative medicine / Autologous cell therapy Ophthalmology / Regenerative Medicine Biologic Live · refreshed every 30 min

Target snapshot

PRFM treatment (PRFM treatment) — The New York Eye & Ear Infirmary. PRFM (platelet-rich fibrin matrix) treatment uses autologous platelet-derived growth factors and fibrin scaffolding to promote tissue regeneration and healing.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PRFM treatment TARGET	PRFM treatment	The New York Eye & Ear Infirmary	phase 3	Regenerative medicine / Autologous cell therapy
Intra ovarian by platelet rich plasma	Intra ovarian by platelet rich plasma	Beni-Suef University	phase 3	Regenerative medicine / Autologous cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative medicine / Autologous cell therapy class)

Beni-Suef University · 1 drug in this class
The New York Eye & Ear Infirmary · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PRFM treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/prfm-treatment. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing